SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Eric Fader who wrote (516)4/26/1999 1:55:00 AM
From: DanZ  Read Replies (2) of 5582
 
Eric,

You have pointed out precisely why I decided not to trade my position in GUMM. As things turned out, I would have been better off trading it over the past two months. Unfortunately, there's no way to tell when news will come out that will send the stock significantly higher. Two stocks that I regretfully traded for small profits this year include NITE and TUNE. Both stocks went up over $50 a share after I sold them and I left hundreds of thousands of dollars on the table. I'm certainly not suggesting that GUMM will reach $60 this year, but I think 25 to 30 is likely if Zicam does well or if GumTech wins a supply contract from Watson.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News